Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine. 2010

Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Fengtai District, Beijing, China.

The novel influenza A (H1N1) 2009 virus has emerged to cause the first pandemic of the twenty-first century. Disease outbreaks caused by the influenza A (H1N1) virus have prompted concerns about the potential for a pandemic and have driven the development of vaccines against this subtype of influenza A. In this study, we developed a monovalent influenza A (H1N1) split vaccine and evaluated its effects in BALB/c mice. Mice were immunized subcutaneously with 2 doses of the vaccine containing hemagglutinin (HA) alone or HA plus an aluminum hydroxide (Al(OH)(3)) adjuvant. Immunization with varying doses of HA (3.75, 7.5, 15, 30, 45 or 60 microg) was performed to induce the production of neutralizing antibodies. The vaccine elicited strong hemagglutination inhibition (HI) and microneutralization, and addition of the adjuvant augmented the antibody response. A preliminary safety evaluation showed that the vaccine was not toxic at large doses (0.5 ml containing 60 microg HA+600 microg Al(OH)(3) or 60 microg HA). Moreover, the vaccine was found to be safe at a dose of 120 microg HA+1200 microg Al(OH)(3) or 120 microg HA in 1.0 ml in rats. In conclusion, the present study provides support for the clinical evaluation of influenza A (H1N1) vaccination as a public health intervention to mitigate a possible pandemic. Additionally, our findings support the further evaluation of the vaccine used in this study in primates or humans.

UI MeSH Term Description Entries
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D004306 Dose-Response Relationship, Immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. Immunologic Dose-Response Relationship,Relationship, Immunologic Dose-Response,Dose Response Relationship, Immunologic,Dose-Response Relationships, Immunologic,Immunologic Dose Response Relationship,Immunologic Dose-Response Relationships,Relationship, Immunologic Dose Response,Relationships, Immunologic Dose-Response
D005260 Female Females
D006388 Hemagglutinins Agents that cause agglutination of red blood cells. They include antibodies, blood group antigens, lectins, autoimmune factors, bacterial, viral, or parasitic blood agglutinins, etc. Isohemagglutinins,Exohemagglutinins,Hemagglutinin
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000536 Aluminum Hydroxide A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc. Hydrated Alumina,Aldrox,Algeldrate,Alhydrogel,Alugel,Amphojel,Basalgel,Brasivil,Dialume,Nephrox,Pepsamer,Rocgel,Alumina, Hydrated,Hydroxide, Aluminum
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
December 2009, The New England journal of medicine,
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
January 2011, Vaccine,
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
November 2009, Vaccine,
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
December 2009, The New England journal of medicine,
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
August 2011, Vaccine,
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
December 2011, Pediatric blood & cancer,
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
December 2010, Expert review of vaccines,
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
November 2011, Journal of acquired immune deficiency syndromes (1999),
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
February 2011, Vaccine,
Penghui Yang, and Li Xing, and Chong Tang, and Weihong Jia, and Zhongpeng Zhao, and Kun Liu, and Xiao Gao, and Xiliang Wang
February 2019, Journal of microbiology (Seoul, Korea),
Copied contents to your clipboard!